PERSONALIZED APPROACH TO USING MIFEPRISTONE IN PATIENTS WITH UTERINE MYOMA


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To study the gene expression of steroid receptors (mER, PR-A, GR, and AR) in the blood mononuclear cells from patients with uterine myoma in relation to the efficiency of therapy with mifepristone. Subjects and methods. The investigation enrolled 50 patients whose myomas were smaller than a 12 week pregnancy (interstitial, interstitial-subserous nodules). Oral mifepristone (gynestril, Stada) 50 mg was given daily for 3 months. The gene expression of the receptors in the patients’ mononuclear cell fraction was determined by RT-PCR. Results. 5-fold greater gene expression of nuclear glucocorticoid receptors (p = 0.02) was seen in patients with no mifepristone effect on myoma sizes. Conclusion. The receptor profile of the mononuclear cell fraction may serve as indirect prognostic sign of the efficiency and expediency of using mifepristone in the therapy of patients with uterine myoma.

全文:

受限制的访问

作者简介

Elena Kareva

Academician P.V. Sergeev Department of Molecular Pharmacology and Radiobiology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: elenakareva@mail.ru
DM, Professor of Academician Moscow 117997, Ostrovitianov str. 1, Russia

Lamara Bekhbudova

Academician P.V. Sergeev Department of Molecular Pharmacology and Radiobiology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: Lamarabekh@gmail.com
Assistant of Department of Pharmacology Pediatric Faculty Moscow 117997, Ostrovitianov str. 1, Russia

Olga Gorenkova

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: olga-gore@mail.ru
Candidate of Medical Science, gynecologist and endocrinologist Moscow 101000, Pokrovka str. 22a, Russia

Tatiana Samoilova

N.I. Pirogov National Medical Surgical Center

Email: tesamoylova@mail.ru
MD, Professor of Department of Women’s Diseases and Reproductive Health Moscow 105203, Nizhnyaya Pervomayskaya str. 70, Russia

参考

  1. Самойлова Т.Е. Медикаментозное лечение лейомиомы матки антигестагенами: возможности и перспективы. Охрана материнства и детства. 2012; 1-19: 102-9.
  2. Волков В.Г., Гусева Н.В., Горшкова И.А. Оптимизация консервативного лечения миомы матки антипрогестеронами и оценка влияния проводимой терапии на качество жизни женщин. Вестник новых медицинских технологий. 2011; 18(1): 92-3.
  3. Wilkens J., Chwalisz K., Han C., Walker J., Cameron I.T., Ingamells S. et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J. Clin. Endocrinol. Metab. 2008; 93(12): 4664-71.
  4. Rabe T., Ahrendt H.J., Albring C., Bitzer J., Bouchard P., Cirkel U. et al. Ulipristal acetate for symptomatic uterine fibroids and myoma-related hypermenorrhea. J. Reproduktionsmed. Endokrinol. 2013; 10(1): 82-101.
  5. Карева Е.Н. Мифепристон и миома матки. Фарматека. 2010; 14: 18-30.
  6. Патент на изобретение № 2312354, РФ. Способ диагностики эстроген- и прогестеронзависимой патологии гениталий. Карева Е.Н., Гаспарян Н.Д., Горенкова О.С., Маняхина А.Е. Заявлено 7 июля 2006, опубл. 10 декабря 2007. [
  7. Klein S.L., Roberts C.W. Sex hormones and immunity to infection. Berlin, Heidelberg: Springer-Verlag; 2010. 319 p.
  8. Карева Е.Н., Ганковская Л.В. Половые стероиды и иммунитет. Российский иммунологический журнал. 2012; 6(1): 3-13.
  9. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008; 3(6): 1101-8.
  10. Esteve J.L., Acosta R., Pérez Y., Rodriguez B., Seigler I., Sanchez C., Tomasi G. Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial. Int. J. Womens Health. 2013; 5: 361-9.
  11. Engman M., Granberg S., Williams A.R., Meng C.X., Lalitkumar P.G., Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum. Reprod. 2009; 24(8): 1870-9.
  12. Djebli N., Fabre D., Boulenc X., Fabre G., Sultan E., Hurbin F. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics. Drug Metab. Dispos. 2015; 43(4): 510-22.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2015
##common.cookie##